Epigenomic signatures of sarcomaid differentiation guide treatment of renal cell carcinoma

Clinical Cancer Research: Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

New Data At Asco 2024 Demonstrating Accurate Her2 Status Detection Across Multiple Cancers and The Ability To Quantify Er Pathway Activation In Breast Cancer From A Simple Blood Test

Novel Epigenomic Liquid Biopsy Assay Predict Estrogen Recepr (ER) Status and Infer ER Pathway Activation in Breast Cancer

Classification of HER2 Status Across Multiple Cancers Using Epigenomic Profiles from A Novel Liquid Biopsy Assay

Presents Poster at 21st Annual Meeting of Association of Cancer Immunorapy (CIMT) in Mainz, Germany

Chief Executive Officer Ivan Cheung Named 2024 Time100 Health List

Novel Liquid Biopsy-based Determination of Lung Cancer Histology Using a Comprehensive Epigenomic Platform Reveals Enhancer Activity as A Key Determinant for Accurate Classification

Data Presented at AACR 2024 Precede Biosciences’ Power Impact Precision Medicine from a Simple Blood Test

A Novel Epigenomic Profiling Assay Reveals Disease Biology and Therapeutic Targets in Gastro-esophageal Cancer from 1mL of Plasma

Comprehensive Epigenomic Profiling from Plasma Inform Therapy Selection: A Proof-of-Concept Study in Cancer

Precede Biosciences Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases

Gordon J. Freeman, PhD, FAACR, Recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology I AACR I News Releases

First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors

Closing of Series B Financing Extension Led by Catalio Capital Management